Perioperative cardiac risk of patient received anthracycline chemotherapy

Background Anthracyclines are one of the most effective anti-tumors antibiotics and they are widely used in hematologic and solid tumors like lymphoma, soft-tissue tumor, gastric cancer, breast cancer and ovarian cancer. But it was reported to have serious side-effects including cardiotoxicity of myocardium and myelosuppression after the first use. Objective This review is aim to discuss the cardiotoxity of general anesthetics in anthracycline exposed patient during perioperative period. Content The cardiotoxity after anthracycline neoadjuvant chemotherapy, perioperative cardiaovascular events after anthracycline chemotherapy and its protect strategy. Trend The cardiotoxity after anthracycline chemotherapy should take into account to reduce the cardiovascular events in clinical anesthesiology. Key words: Anthracycline; Cardiotoxicity; Anesthetics, general